Valence Discovery

Valence Labs, powered by Recursion, is industrializing scientific discovery to radically improve lives. Their vision is that highly autonomous systems capable of Nobel-worthy insights will usher in a new wave of scientific discovery.

In the AI-powered drug discovery market, Valence Labs stands out for its ability to work with limited sets of data to discover drugs that address unmet needs. Valence was founded by a strong team that raised $10.9 million in funding during and after coming out of stealth. Valence’s potential also caught the eye of an American pharmaceutical company, Recursion, which acquired Valence for $63.4 million. After the acquisition, Recursion secured $50 million in funding from Nvidia, which recognized the potential that Valence could bring to the team.

In more recent news, Valence Labs has been using the newest AI technology to build the world’s largest Graph Neural Network and lead a new path in drug discovery.

Related Press:

Valence Discovery: transforming AI-enabled drug design with ‘few-shot learning’

Valence Discovery announces $10.9 million CAD for AI-aided drug discovery and formulation

American biotech Recursion acquires two Canadian AI drug-discovery companies, Cyclica and Valence

AFTER BUYING CYCLICA AND VALENCE, RECURSION SECURES $50 MILLION USD FROM NVIDIA FOR AI DRUG DISCOVERY

Valence Labs uses OCI to help build largest GNN in drug discovery

LinkedIn: https://www.linkedin.com/company/valenceailabs/
‍